JNPMEDI has attracted 2 billion won worth of seed investment from Ajou IB Investment, Murex Partners, and Gentium Partners, including Kakao Ventures' commitment to attract investment.
JNPMEDI is a company established in July 2020 that provides a medical data platform called "Maven Clinical Cloud (hereinafter referred to as Maven)." It is actively collaborating with various stakeholders in the industry to collect, monitor, and analyze medical data based on digital technologies such as blockchain and cloud, and to secure operational excellence throughout the management process.
JNPMEDI's main service, "Maven," has secured more than 20 customers since its launch in February this year and is widely used not only in pharmaceutical-related clinical trials such as phase 1 to phase 3, PMS (Post Marketing Surveillance), and observational research, but also in clinical trials with advanced digital technologies such as artificial intelligence (AI) medical devices and digital therapy devices (DTx).
The investors praised the digital healthcare market, which includes JNPMEDI, for its steep growth due to increased demand through COVID-19. It also showed expectations for having differentiated capabilities compared to competitors by preemptively securing Decentralized Clinical Trials (DCT) technology in response to non-face-to-face trends.